|Delayed - 01/19 03:59:58 pm|
LEXARIA BIOSCIENCE CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
|11/06/2020 | 09:23am|
Item 7.01 Regulation FD Disclosure.
strategic initiatives for 2021 whereby the focus of its business will be on the
out-licensing of its patented DehydraTECH drug delivery technology within four
core areas of business:
· Heart disease including hypertension utilizing CBD;
· Reduced-risk methods of delivering non-combusted nicotine;
· Improving antiviral drug delivery for applications that include Covid-19,
influenza, herpes, hepatitis and AIDS; and
· Hemp-based CBD business-to-business ("B2B") applications for
non-pharmaceutical consumer and therapeutic or medicinal products and
prospective pharmaceutical indications beyond hypertension.
Item 9.01 Financial Statements And Exhibits.
Exhibit No. Description
99.1 Press Release issued
© Edgar Online, source